Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in northeast China

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 9, 2011, Pages 2411-2417

  Lv, Minhao ^a   Li, Beibei ^b   Li, Yongfeng ^a   Mao, Xiaoyun ^a   Yao, Fan ^a   Jin, Feng ^a  

^a The First Affiliated Hospital of China Medical University   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Chemotherapy; Molecular subtype; Pathologic complete remission; Predictive factor

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; HER2 PROTEIN, HUMAN; PROGESTERONE RECEPTOR; TAXOID;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST TUMOR; CHINA; FEMALE; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; CHINA; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAXOIDS;

EID: 84866333922     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Fisher B, Brown A, Mamounas E, et al. (1997). Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol, 15, 2483-93.
2. Mieog JS, van der Hage JA, van de Velde CJ. (2007). Neoadjuvant chemotherapy for operable breast cancer. Br J Surg, 94, 1189-200.
3. Rastogi P, Anderson SJ, Bear HD, et al. (2008). Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol, 26, 778-85.
4. Van Der Hage JA, van de Velde CJ, Julien JP, et al. (2001). Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol, 19, 4224-37.
5. Kim SI, Sohn J, Koo JS, et al. (2010). Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Oncology, 79, 324-30.
6. Carey LA, Perou CM, Livasy CA, et al. (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295, 2492-502.
7. Hugh J, Hanson J, Cheang MC, et al. (2009). Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol, 27, 1168-76.
8. Nielsen TO, Hsu FD, Jensen K, et al. (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res, 10, 5367-74.
9. Cheang MC, Voduc D, Bajdik C, et al. (2008). Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res, 14, 1368-76.
10. Livasy CA, Karaca G, Nanda R, et al. (2006). Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol, 19, 264-71.
11. Carey LA, Dees EC, Sawyer L, et al. (2007). The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res, 13, 2329-34.
12. James K, Eisenhauer E, Christian M, et al. (1999). Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst, 91, 523-8.
13. Perou CM, Sorlie T, Eisen MB, et al. (2000). Molecular portraits of human breast tumours. Nature, 406, 747-52.
14. Peppercorn J, Perou CM, Carey LA (2008). Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest, 26, 1-10.
15. De Ronde JJ, Hannemann J, Halfwerk H, et al. (2010). Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat, 119, 119-26.
16. Huober J, von Minckwitz G, Denkert C, et al. (2010). Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat, 124, 133-40.
17. Bhargava R, Beriwal S, Dabbs DJ, et al. (2010). Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: A single institutional experience with 359 cases. Cancer, 116, 1431-9.
18. Straver ME, Rutgers EJ, Rodenhuis S, et al. (2000).The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol, 17, 2411-8.
19. Fisher B, Bryant J, Wolmark N, et al. (1998). Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol, 16, 2672-85.
20. Rastogi P, Anderson SJ, Bear HD, et al. (2008). Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol, 26, 778-85.
21. Carey LA, Metzger R, Dees EC, et al. (2005). American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst, 97, 1137-42.
22. Parker JS, Mullins M, Cheang MC, et al. (2009). Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol, 27, 1160-7.
23. Blows FM, Driver KE, Schmidt MK, et al. (2010). Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med, 7, e1000279.
24. Rodenhuis S, Mandjes IA, Wesseling J, et al. (2010). A simple system for grading the response of breast cancer to neoadjuvant chemotherapy. Ann Oncol, 21, 481-7.
25. Kim R, Osaki A, Toge T (2005). Current and future roles of neoadjuvant chemotherapy in operable breast cancer. Clin Breast Cancer, 6, 223-32.
26. Peintinger F, Symmans WF, Gonzalez-Angulo AM, et al. (2006). The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer, 107, 1248-54.
27. Thomas A, Ohlinger R, Hauschild M, et al. (2006). Options and limits of surgery after pre-operative chemotherapy in breast cancer. Anticancer Res, 26, 1677-82.
28. Chang HR, Glaspy J, Allison MA, et al. (2010). Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer, 116, 4227-37.
29. Staudacher L, Cottu PH, Diéras V, et al. (2011). Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol, 22, 848-56.
30. Gogas H, Pectasides D, Kostopoulos I, et al. (2010). Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II trial of the Hellenic Cooperative Oncology Group. Clin Breast Cancer, 10, 230-7.
31. Goldstein NS, Decker D, Severson D, et al. (2007). Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer, 110, 1687-96.
32. Andre F, Mazouni C, Liedtke C, et al. (2008). HER2 expression and efficacy of preoperative paclitaxel/ FAC chemotherapy in breast cancer. Breast Cancer Res Treat, 108, 183-90.